Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.40 and traded as high as $4.44. Achieve Life Sciences shares last traded at $4.36, with a volume of 71,613 shares changing hands.
Analysts Set New Price Targets
Several brokerages have issued reports on ACHV. Lake Street Capital dropped their target price on Achieve Life Sciences from $19.00 to $11.00 and set a "buy" rating on the stock in a research report on Tuesday, March 5th. Oppenheimer restated an "outperform" rating and issued a $18.00 target price on shares of Achieve Life Sciences in a research note on Monday, April 1st.
Check Out Our Latest Stock Report on ACHV
Achieve Life Sciences Price Performance
The stock has a 50 day simple moving average of $4.45 and a two-hundred day simple moving average of $4.40. The firm has a market cap of $149.33 million, a PE ratio of -2.85 and a beta of 1.32. The company has a debt-to-equity ratio of 4.02, a quick ratio of 0.82 and a current ratio of 0.82.
Hedge Funds Weigh In On Achieve Life Sciences
A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Achieve Life Sciences by 2.0% during the 4th quarter. Vanguard Group Inc. now owns 605,710 shares of the biopharmaceutical company's stock valued at $2,496,000 after buying an additional 11,757 shares during the last quarter. Northern Trust Corp raised its stake in shares of Achieve Life Sciences by 29.2% during the 4th quarter. Northern Trust Corp now owns 101,984 shares of the biopharmaceutical company's stock valued at $420,000 after buying an additional 23,027 shares during the last quarter. Madison Park Capital Advisors LLC purchased a new position in shares of Achieve Life Sciences during the 4th quarter valued at about $41,000. Raymond James & Associates raised its stake in shares of Achieve Life Sciences by 6.0% during the 4th quarter. Raymond James & Associates now owns 154,829 shares of the biopharmaceutical company's stock valued at $638,000 after buying an additional 8,729 shares during the last quarter. Finally, LPL Financial LLC grew its position in shares of Achieve Life Sciences by 11.1% during the 3rd quarter. LPL Financial LLC now owns 164,500 shares of the biopharmaceutical company's stock valued at $707,000 after acquiring an additional 16,500 shares during the period. Hedge funds and other institutional investors own 33.52% of the company's stock.
About Achieve Life Sciences
(
Get Free Report)
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
Featured Stories
Before you consider Achieve Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Achieve Life Sciences wasn't on the list.
While Achieve Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
